 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Uromed is a company that makes a product called the "Reliance Insert". Similar to a tampon in its use, a small balloon stops urine flow, it is designed to control stress incontinence in women. The market is huge (8.5 million in U.S.A. alone) for this product, it is an under-reported problem in women. The company is already selling the insert in Europe, and is awaiting FDA approval in the U.S. It has been a huge success in Europe, signing marketing deals with large well known European companies. Clinical studies found that: The Reliance Insert effectively controlled urine loss in 97% of patients. Patients responding to a 12-month questionnaire reported positive results... 90% experienced quality of life improvements 97% would strongly recommend the Reliance Insert to another female incontinence sufferer URMD earlier this month had 2 glowing reports from members of the American Urological Association, when they met in Orlando FL on May 8th. I bought at 10 late last year, if I had more to invest I would buy more. I think FDA approval is just a matter of time. How about 30+ by the end of the year... what do you think? | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |